Chief
W. Marston Linehan, M.D.
LEAD PROGRAM ASSISTANT
Georgia F. Shaw, M.S.

Center for Cancer Research
National Cancer Institute

Building 10, Room 1-5940
Bethesda, MD 20892-1107
301-496-6353

The Urologic Oncology Branch conducts clinical and basic research designed to develop better methods for detecting, preventing, and treating patients with kidney cancer, prostate cancer and bladder cancer. We evaluate and manage patients with non-inherited as well as inherited forms of kidney cancer. The Branch also has an expanding prostate cancer program. Patients with known or suspected localized and locally advanced prostate cancer undergo advanced MRI imaging followed by fusion image-guided biopsy to diagnose and characterize the cancer. They may then be managed with robotic surgery or be followed with active surveillance and intermittent imaging. In addition, we have a growing program in genomics and targeted therapy for bladder cancer patients, including therapy that targets EGFR, FGFR3 and other mutated bladder cancer genes.W. Marston Linehan 

 
W. Marston Linehan
Chief, Urologic Oncology Branch
 
  • News

    The JAMA Report:  MRI/Ultrasound Fusion Biopsy for Prostate Cancer

  • Our Science

    The Long Road to Understanding Kidney Cancer

  • Our Clinical Trials

    link to uob clinical trialsinclude renal cell, prostate, and bladder cancers, as well as urologic malignant disorders.

  • Training

    link to uob training informationNumerous opportunities are available for training in both clinical and basic research areas with the Urologic Oncology Branch.

Support Services

Dr Linehan, staff and a patient discuss options

As part of our comprehensive care we provide natural history protocols pertaining to rare inherited and sporadic urologic malignant disorders. We treat these disorders with targeted molecular drug therapies and innovative surgical procedures. Our patients are provided guidance and assistance with appointments, travel, counseling and social support throughout the process and follow up. We also believe strongly in collaborating with your primary care physican (with your permission) to form your "expert care team." Before your first visit, we may ask you to provide medical records, CDs with MRIs, CTs, or PET scans, and a list of medications.

  • Consultations are at no cost to the patient.
  • After a patient is accepted on a study, treatments, tests and other services at the NIH Clinical Center are also no cost.
  • NIH does not cover expenses for medical services at other facilities.
  • We are located on the NIH campus in Bethesda, Maryland, approximately 8 miles north of Washington, D.C.
  • The Urologic Oncology Branch Clinic is on the 3rd floor of the Magnuson Clinical Center (Building 10).
  • Visitor information is available at NIH Clinical Center - Access and Directions (View Map).

Genetics Counseling

We help patients with rare cancer susceptibility conditions understand the clinical and genetic basis of their condition and the importance of the surveillance plan that will be necessary throughout their life span.  We meet with our patients to determine the appropriate genetic analysis to perform based on their personal and family medical history, renal tumor pathology, physical and dermatologic examinations and the results of other clinical evaluations. 

UOB Autosomal Dominance Inheritance Chart

Dr. Linehan and a patient

Main Administrative Office:  301-496-6353

  • Available Monday - Friday, 8:30 AM - 5:00 PM
  • Patient Records:  301-496-5981

Referrals and Information about Trials

  • Kidney
    • Information about Trials:  301-402-7913 | 301-435-8897
    • Current Patients:  301-402-6507 | 301-451-8121
  • Prostate
    • Information about Trials:  301-402-4346  |  301-496-0329 
    • Current Patients:  301-402-4346
    • Referrals from Physicians:  240-826-2122
  • Bladder
    • Information about Trials:  301-435-6255  |  301-827-1480
    • Current Patients:  301-827-1007 |  301-827-1480

Our oncology nurses and practitioners understand both the genetic basis of prostate and urologic cancers and the rationale behind emerging clinical trials.  Their knowledge of the basic principles of genetics, tumorigenesis, diagnostics, treatment and surveillance modalities is incorporated into our protocols and practice. When surgery is indicated, the Urologic Oncology Branch offers state-of-the-art procedures.  Clinical trial coordinators guide patients and their families through our targeted therapies, and provide assurance by carefully explaining the treatment plan. In addition, genetic counselors provide further information for a wider perspective of various conditions.

 

Clinical Programs Overview

uob physician and patientOur physicians study families who have rare inherited conditions which predispose to development of kidney cancer. We also see patients without a positive family history who are suspected to have one of these rare genetic conditions.  It is the study of these patients and their family members that allow the discovery of new genetic conditions, the responsible genes and new understanding that is the foundation of this Branch and has allowed the successes of the Branch. The clinical team is comprised of one genetic counselor/ protocol manager, nurse practitioners, clinical research nurses and patient care coordinators.  Several populations of patients are evaluated for sporadic renal and bladder cancer, sporadic prostate cancer, familial kidney cancer, and interventional clinical trials.

Molecular Therapeutics

Molecular Therapeutics translates discoveries at the genetic, molecular and cellular levels into improvements in the diagnosis and treatment of genitourinary (GU) cancers by defining genetically identified oncogenic signaling pathways, identifying new therapeutic targets and strategies, and conducting preclinical and clinical drug and biomarker development. We believe that successful therapeutic strategies to treat GU cancers will require understanding how cancer-associated signaling defects affect cell and organ function, as well as the development of appropriate reagents, bioassays, and cell and animal models for pathway analysis, drug design and testing.

Our Physicians

W. Marston Linehan, M.D.Peter A. Pinto, M.D.Piyush Agarwal, M.D., Ramaprasad Srinivasan, M.D., and Adam Metwalli, M.D.

Our Nurse Practitioners

Nana Yaqub Ogun, P.A., Julie Friend, P.A., and Maria Trattler, P.A.

Our Patient Care Coordinators

Cris Leite, Gabriela Coello, Yvonne Wall, and Lerkia Parks

 

 

"The Long Road to Understanding Kidney Cancer" is an article that spotlights Dr. W. Marston Linehan's investigation of gene pathways in kidney cancer.

W Marston Linehan investigates kidney cancer gene pathways to find new treatment strategies

Video interviews from this article:

 

 

The JAMA Report:  MRI/Ultrasound Fusion Biopsy for Prostate Cancer

This video spotlights exciting new research being conducted by Dr. Peter A. Pinto

About

The Urologic Oncology Branch conducts clinical and basic research designed to develop better methods for detecting, preventing, and treating patients with kidney cancer, prostate cancer and bladder cancer. We evaluate and manage patients with non-inherited as well as inherited forms of kidney cancer. The Branch also has an expanding prostate cancer program. Patients with known or suspected localized and locally advanced prostate cancer undergo advanced MRI imaging followed by fusion image-guided biopsy to diagnose and characterize the cancer. They may then be managed with robotic surgery or be followed with active surveillance and intermittent imaging. In addition, we have a growing program in genomics and targeted therapy for bladder cancer patients, including therapy that targets EGFR, FGFR3 and other mutated bladder cancer genes.W. Marston Linehan 

 
W. Marston Linehan
Chief, Urologic Oncology Branch
 
  • News

    The JAMA Report:  MRI/Ultrasound Fusion Biopsy for Prostate Cancer

  • Our Science

    The Long Road to Understanding Kidney Cancer

  • Our Clinical Trials

    link to uob clinical trialsinclude renal cell, prostate, and bladder cancers, as well as urologic malignant disorders.

  • Training

    link to uob training informationNumerous opportunities are available for training in both clinical and basic research areas with the Urologic Oncology Branch.

Referrals

Dr. Linehan and a patient

Main Administrative Office:  301-496-6353

  • Available Monday - Friday, 8:30 AM - 5:00 PM
  • Patient Records:  301-496-5981

Referrals and Information about Trials

  • Kidney
    • Information about Trials:  301-402-7913 | 301-435-8897
    • Current Patients:  301-402-6507 | 301-451-8121
  • Prostate
    • Information about Trials:  301-402-4346  |  301-496-0329 
    • Current Patients:  301-402-4346
    • Referrals from Physicians:  240-826-2122
  • Bladder
    • Information about Trials:  301-435-6255  |  301-827-1480
    • Current Patients:  301-827-1007 |  301-827-1480

Our oncology nurses and practitioners understand both the genetic basis of prostate and urologic cancers and the rationale behind emerging clinical trials.  Their knowledge of the basic principles of genetics, tumorigenesis, diagnostics, treatment and surveillance modalities is incorporated into our protocols and practice. When surgery is indicated, the Urologic Oncology Branch offers state-of-the-art procedures.  Clinical trial coordinators guide patients and their families through our targeted therapies, and provide assurance by carefully explaining the treatment plan. In addition, genetic counselors provide further information for a wider perspective of various conditions.

 

For Patients

Support Services

Dr Linehan, staff and a patient discuss options

As part of our comprehensive care we provide natural history protocols pertaining to rare inherited and sporadic urologic malignant disorders. We treat these disorders with targeted molecular drug therapies and innovative surgical procedures. Our patients are provided guidance and assistance with appointments, travel, counseling and social support throughout the process and follow up. We also believe strongly in collaborating with your primary care physican (with your permission) to form your "expert care team." Before your first visit, we may ask you to provide medical records, CDs with MRIs, CTs, or PET scans, and a list of medications.

  • Consultations are at no cost to the patient.
  • After a patient is accepted on a study, treatments, tests and other services at the NIH Clinical Center are also no cost.
  • NIH does not cover expenses for medical services at other facilities.
  • We are located on the NIH campus in Bethesda, Maryland, approximately 8 miles north of Washington, D.C.
  • The Urologic Oncology Branch Clinic is on the 3rd floor of the Magnuson Clinical Center (Building 10).
  • Visitor information is available at NIH Clinical Center - Access and Directions (View Map).

Genetics Counseling

We help patients with rare cancer susceptibility conditions understand the clinical and genetic basis of their condition and the importance of the surveillance plan that will be necessary throughout their life span.  We meet with our patients to determine the appropriate genetic analysis to perform based on their personal and family medical history, renal tumor pathology, physical and dermatologic examinations and the results of other clinical evaluations. 

UOB Autosomal Dominance Inheritance Chart

Teams

Clinical Programs Overview

uob physician and patientOur physicians study families who have rare inherited conditions which predispose to development of kidney cancer. We also see patients without a positive family history who are suspected to have one of these rare genetic conditions.  It is the study of these patients and their family members that allow the discovery of new genetic conditions, the responsible genes and new understanding that is the foundation of this Branch and has allowed the successes of the Branch. The clinical team is comprised of one genetic counselor/ protocol manager, nurse practitioners, clinical research nurses and patient care coordinators.  Several populations of patients are evaluated for sporadic renal and bladder cancer, sporadic prostate cancer, familial kidney cancer, and interventional clinical trials.

Molecular Therapeutics

Molecular Therapeutics translates discoveries at the genetic, molecular and cellular levels into improvements in the diagnosis and treatment of genitourinary (GU) cancers by defining genetically identified oncogenic signaling pathways, identifying new therapeutic targets and strategies, and conducting preclinical and clinical drug and biomarker development. We believe that successful therapeutic strategies to treat GU cancers will require understanding how cancer-associated signaling defects affect cell and organ function, as well as the development of appropriate reagents, bioassays, and cell and animal models for pathway analysis, drug design and testing.

Our Physicians

W. Marston Linehan, M.D.Peter A. Pinto, M.D.Piyush Agarwal, M.D., Ramaprasad Srinivasan, M.D., and Adam Metwalli, M.D.

Our Nurse Practitioners

Nana Yaqub Ogun, P.A., Julie Friend, P.A., and Maria Trattler, P.A.

Our Patient Care Coordinators

Cris Leite, Gabriela Coello, Yvonne Wall, and Lerkia Parks

 

 

For Trainees

Our Science

"The Long Road to Understanding Kidney Cancer" is an article that spotlights Dr. W. Marston Linehan's investigation of gene pathways in kidney cancer.

W Marston Linehan investigates kidney cancer gene pathways to find new treatment strategies

Video interviews from this article:

 

 

News

The JAMA Report:  MRI/Ultrasound Fusion Biopsy for Prostate Cancer

This video spotlights exciting new research being conducted by Dr. Peter A. Pinto